About Us

Gene Therapies to Slow, Stop and Reverse the Neurodegenerative Process

At Prevail Therapeutics, we are developing a pipeline of gene therapies to cure the underlying disease process for patients with Parkinson’s disease and other neurodegenerative and lysosomal disorders. We are focused on leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs target patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of these disorders.

Prevail was founded in a collaborative effort by Asa Abeliovich, M.D., Ph.D., OrbiMed and The Silverstein Foundation for Parkinson’s with GBA, who shared a common vision: to eradicate Parkinson’s disease and related disorders. We aim to translate recent advances in our understanding of the root genetic causes of these diseases into therapeutics for patients. Through a partnership with REGENXBIO, we are utilizing the NAV AAV9 vector technology to advance a pipeline of gene therapy programs into therapies for patients in need.

Prevail was launched in 2017 with a world-class leadership team, partners and investors. We are headquartered in New York City at the Alexandria Center for Life Science.


Executive Team

Asa Abeliovich, M.D., Ph.D.

Founder & CEO

Yong Dai, Ph.D.

Chief Technology Officer

Franz Hefti, Ph.D.

Chief Development Officer

Brett Kaplan

Brett Kaplan, M.D.

Chief Financial Officer


Emily Minkow

Chief Business Officer

Jeffrey Sevigny, M.D.

Chief Medical Officer

Board of Directors


Francois Nader, M.D.

Non-Executive Chairman

Asa Abeliovich, M.D., Ph.D.

Founder & CEO

Tim Adams



Carl L. Gordon, Ph.D., CFA


Ran Nussbaum



Peter Thompson, M.D.





REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.

REGENXBIO and its third-party NAV Technology Platform licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Prevail has an exclusive worldwide license agreement with REGENXBIO to develop and commercialize gene therapy products using REGENXBIO’s NAV AAV9 vector for the treatment of Parkinson’s disease and other related neurodegenerative diseases.

The Silverstein Foundation for Parkinson’s with GBA

The Silverstein Foundation for Parkinson’s with GBA is a non-profit organization that invests in cutting edge research with the goal of discovering new therapies for the treatment of Parkinson's disease in glucocerebrosidase (GBA1) mutation carriers. The Silverstein Foundation was founded in 2017 by Jonathan Silverstein, General Partner and Co-Head of Global Private Equity at OrbiMed, following his own diagnosis of Parkinson’s disease and learning he was a carrier of the GBA mutation.

Jonathan and The Silverstein Foundation helped form Prevail in 2017 to bring forward curative therapies for patients.